Yupelri (Revefenacin) Patent Expiration, LOE Window & CMS Spending
Yupelri (Revefenacin) by Viatris: FDA Orange Book core substance LOE 2031-08-25 (last listed 2039-10-23), 0 AB generics, $27.2M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Viatris |
| FDA Application & Pathway | N210598 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-08-25 |
| Last Listed Patent or Exclusivity Date | 2039-10-23 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $27.2M |
| 2024 Medicare Part D Spend | $7.2M |
| 2024 Medicaid Spend | $20.0M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 29.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.